MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: EASL 2025
MedXY News
EnglishTag

EASL 2025

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseasebreast cancerepidemiology

Latest news

Tag

Reevaluating EASL 2025 Criteria: Benefits of Nucleos(t)ide Analogues in Chronic Hepatitis B Beyond Current Recommendations
Gastroenterologycirrhosischronic hepatitis B

Reevaluating EASL 2025 Criteria: Benefits of Nucleos(t)ide Analogues in Chronic Hepatitis B Beyond Current Recommendations

By MedXY|Oct 20, 2026

This study demonstrates that nucleos(t)ide analogue therapy significantly reduces cirrhosis and hepatocellular carcinoma risk in specific HBeAg-positive chronic HBV infection phases beyond current EASL 2025 treatment indications.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models